<DOC>
	<DOCNO>NCT01541332</DOCNO>
	<brief_summary>The purpose clinical research study evaluate safety effectiveness ( good bad effect ) combination three different drug , pomalidomide , pegylated liposomal doxorubicin , dexamethasone use treat relapse ( disease come back ) refractory ( disease respond past treatment ) multiple myeloma . Different dosage ( amount study drug ) pomalidomide first test determine side effect risk associate combine study drug two list . Once optimal dose decide , study change focus determine effectiveness study drug combination .</brief_summary>
	<brief_title>Pomalidomide , Dexamethasone Pegylated Liposomal Doxorubicin Relapsed/Refractory Multiple Myeloma</brief_title>
	<detailed_description>This phase 1/2 , multicenter , open label nonrandomized study evaluate efficacy safety pomalidomide daily dosage 2 , 3 4 mg combination intravenous ( IV ) dexamethasone 40 mg/dose Pegylated Liposomal Doxorubicin ( PLD ) 5 mg/m2/dose subject relapsed/refractory multiple myeloma ( MM ) . The study consist screen period , follow eight 28 day open label treatment cycle , final assessment occur 28 day end last treatment , follow-up period . Subjects eligible study receive treatment study drug maximum eight 28 day treatment cycle . Subjects treat maximum response plus 2 additional cycle ( 8 cycle allow ) complete 8 cycle therapy without disease progression . Pomalidomide , dexamethasone PLD administer appropriate cycle day show . Cohort 1 Pomalidomide* - 2 mg , Dexamethasone** - 40 mg , PLD** - 5 mg/m2 Cohort 2 Pomalidomide* - 3 mg , Dexamethasone** - 40 mg , PLD** - 5 mg/m2 Cohort 3 Pomalidomide* - 4 mg , Dexamethasone** - 40 mg , PLD** - 5 mg/m2 * PO Days 1-21 ** IV Days 1 , 4 , 8 11 In cohort , unacceptable dose limit toxicity ( DLT ) see 3 subject first cycle dose level , dose escalation continue . All subject cohort must complete minimum 28 day full cycle , whichever long , without DLT enrollment next cohort begin . If DLT identify 1 subject dose level first treatment cycle , additional 3 subject recruit dose level . A maximum 6 subject may enrol cohort . If unacceptable DLT observe 2 subject dose level , subject recruit dose level . The maximum tolerated dose ( MTD ) declare high dose level few 33 % subject experience unacceptable DLT . If pomalidomide 4 mg reach few 33 % subject experience unacceptable DLT , 4 mg accept putative MTD . Once MTD establish , enrollment continue expand dose cohort total sample size 40 subject reach entire study . During phase 2 portion study , subject enrol relapsed/refractory MM resistant lenalidomide demonstrate progressive disease lenalidomide relapse within 8 week last dose lenalidomide .</detailed_description>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Pomalidomide</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<criteria>Diagnosis MM base standard criterion ( Durie 1986 ) Currently MM measurable disease , define : monoclonal immunoglobulin spike serum electrophoresis least 0.5 g/dL and/or urine monoclonal protein level least 200 mg/24 hour patient without measurable serum urine Mprotein level , abnormal free light chain ratio ( normal value : 0.26 1.65 ) Currently progressive MM relapse refractory , define : For phase 1 : Relapsed follow stabilization response least one antimyeloma regimen refractory define progressed receive antimyeloma treatment For phase 2 : Refractory lenalidomide demonstrate progressive disease lenalidomide relapse within 8 week last dose lenalidomide either single agent combination . Prior treatment four day less total 400 mg prednisone ( equivalent potency another steroid ) MM consider regimen Able adhere study visit schedule protocol requirement ECOG performance status 2 great study entry Lifeexpectancy great 3 month Lab test within study range study entry : Absolute neutrophil count &gt; 1.5 x 109/L Platelet count &gt; 75 x 109/L Hemoglobin &gt; 8 g/dL Calculated measure creatinine clearance &gt; 30 mL/minute Total bilirubin &lt; 1.5 x upper limit normal ( ULN ) AST ( SGOT ) ALT ( SGPT ) &lt; 2 x ULN Serum potassium within normal range Females childbearing potential must negative serum urine pregnancy test . Able take aspirin ( 81 325 mg ) daily prophylactic anticoagulation ( subject intolerant ASA may use warfarin low molecular weight heparin ) POEMS syndrome Plasma cell leukemia Primary amyloidosis Nonhematologic malignancy within past 5 year exception ) adequately treat basal cell carcinoma , squamous cell skin cancer , thyroid cancer ; b ) carcinoma situ cervix breast ; c ) prostate cancer Gleason Grade 6 less stable prostatespecific antigen level ; ) cancer consider cure surgical resection unlikely impact survival duration study , localize transitional cell carcinoma bladder benign tumor adrenal pancreas Impaired cardiac function clinically significant cardiac disease Severe hypercalcemia Any serious medical condition , laboratory abnormality , psychiatric illness would prevent subject sign ICF Any condition , include presence laboratory abnormality , place subject unacceptable risk he/she participate study confounds ability interpret data study Undergone major surgery within 28 day prior enrollment recovered side effect therapy ( Kyphoplasty consider major surgery ; however , investigator discus enrollment subject recent history kyphoplasty medical monitor ) Pregnant breast feeding female . ( Lactating female must agree breast feed take lenalidomide ) Received follow prior therapy : Pomalidomide Chemotherapy within 3 week study drug ( 6 wks nitrosoureas ) Corticosteroids ( &gt; 10 mg/day prednisone equivalent ) within 3 week study drug Immunotherapy antibody therapy well thalidomide , lenalidomide , arsenic trioxide bortezomib within 21 day study drug Extensive radiation therapy within 28 day study drug . Receipt localize radiation therapy preclude enrollment . Use experimental drug therapy within 28 day study drug Known hypersensitivity compound similar chemical biological composition thalidomide , lenalidomide doxorubicin . The development erythema nodosum characterize desquamate rash take thalidomide similar drug Concurrent use anticancer agent treatment Known positivity human immunodeficiency virus ( HIV ) hepatitis B C ; baseline test HIV hepatitis B C require</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>relapse refractory</keyword>
	<keyword>multiple myeloma</keyword>
	<keyword>pomalidomide</keyword>
	<keyword>Doxil</keyword>
	<keyword>dexamethasone</keyword>
	<keyword>Oncotherapeutics</keyword>
</DOC>